Skip to main content

Table 1 GRADE evidence profile of selected studies [12,13,14,15,16,17,18,19,20,21]

From: Clinical outcome of renin-angiotensin-aldosterone system blockers in treatment of hypertensive patients with COVID-19: a systematic review and meta-analysis

Summary of findings

Quality assessment

Study (year)

Settings

Study design

Length of study

Sample size

Grading of Hypertension

Duration of follow-up

Secondary outcomes (comorbidities)

Primary outcomes (all-cause mortality)

Hazard ratio (95% CI)

Checklists

Results

Lee et al. (2020) [13]

Centers for Disease Control and Prevention (Korea)

Retrospective cohort

Jan 2020 until Mar 2020

N = 8266

Minimal grade 1

2 months

Diabetes mellitus, cancer, COPD, stroke, coronary artery disease, heart failure, chronic renal disease

N = 112

1.07 (0.68–1.68)

Limitations

Not serious

Non-ACEi/ARB, 977

ACEi/ARB, 7289

Non-ACEi/ ARB, 62

ACEi/ ARB, 50

Inconsistency

Serious

Indirectness

Not serious

Imprecision

Serious

Publication Bias

Undetected

Quality

High

Li et al. (2020) [12]

Central Hospital of Wuhan (China)

Retrospective cohort

15 Jan 2020 until 15 Mar 2020

N = 362

Minimal grade 1

2 months

Cerebrovascular disease, cardiovascular disease, diabetes, chronic kidney disease

N = 77

0.76 (0.44–1.33)

Limitations

Not serious

Non-ACEi/ARB, 247

ACEi/ARB, 115

Non-ACEi/ ARB, 56

ACEi/ ARB, 21

Inconsistency

Not serious

Indirectness

Not serious

Imprecision

Not serious

Publication Bias

Undetected

Quality

High

Mehra et al. (2020) [14]

Multihospital International Registry (Asia, Europe, and North America)

Retrospective cohort

20 Dec 2019 until 15 Mar 2020

N = 2346

Minimal grade 1

n/a

Heart disease, diabetes mellitus, COPD

N = 184

0.24 (0.17–0.33)

Limitations

Serious

Non-ACEi/ARB, 920

ACEi/ARB, 1426

Non-ACEi/ ARB, 130

ACEi/ ARB, 54

Inconsistency

Not serious

Indirectness

Not serious

Imprecision

Not serious

Publication bias

Undetected

Quality

High

Meng et al. (2020) [17]

Shenzhen Third People’s Hospital (China)

Retrospective cohort

11 Jan 2020 until 23 Feb 2020

N = 42

Grade 2 or grade 3 hypertension according to ESC

n/a

Type 2 diabetes or coronary heart disease

N = 1

0.46 (0.018–12.14)

Limitations

Serious

Non-ACEi/ARB, 25

ACEi/ARB, 17

Non-ACEi/ ARB, 1

ACEi/ ARB, 0

Inconsistency

Serious

Indirectness

Not serious

Imprecision

Not serious

Publication bias

Detected

Quality

Low

Yang et al. (2020) [20]

Hubei Provincial Hospital of Traditional Chinese Medicine (China)

Retrospective cohort

1 Nov 2019 until 31 Dec 2019

N = 126

Minimal grade 1

3 months

Diabetes or cardiopathy

N = 13

0.35 (0.08–1.51)

Limitations

Not serious

Non-ACEi/ARB, 83

ACEi/ARB, 43

Non-ACEi/ARB, 11

ACEi/ARB, 2

Inconsistency

Not serious

Indirectness

Not serious

Imprecision

Serious

Publication bias

Undetected

Quality

Moderate

Zhou et al. [18] (2020)

Wuhan Fourth Hospital, Hubei Province (China)

Retrospective cohort

25 Jan 2020 until 20 Feb 2020

36

Minimal grade 1

25 days

Diabetes, cerebrovascular disease, cardiovascular disease, COPD, chronic kidney disease, malignancy, rheumatoid arthritis

N = 7

0.14 (0.009–2.2)

Limitations

Serious

Non-ACEi/ARB, 21

ACEi/ARB, 15

Non-ACEi/ARB, 5

ACEi/ARB, 2

Inconsistency

Serious

Indirectness

Not serious

Imprecision

Very serious

Publication bias

Detected

Quality

Low

Fosbol et al. (2020) [16]

Danish national administrative registry (Denmark)

Retrospective cohort

22 Feb 2020 until 4 May 2020

N = 4480

Minimal grade 1

End of study period (4 May 2020)

Diabetes, myocardial infarction, cancer, cerebrovascular diseases, COPD, chronic kidney diseases

N = 197

0.94 (0.65–1.37)

Limitations

Not serious

Non-ACEi/ARB, 3585

ACEi/ARB, 895

Non-ACEi/ARB, 36

ACEi/ARB, 161

Inconsistency

Serious

Indirectness

Not serious

Imprecision

Not serious

Publication bias

Undetected

Quality

High

Pan et al. (2020) [21]

Renmin Hospital of Wuhan University (China)

Retrospective single-center study

4 Jan 2020 until 14 Feb 2020

N = 282

Minimal grade 1

30 days

Diabetes, coronary heart diseases, cerebrovascular diseases, chronic liver disease, chronic kidney disease

N = 67

0.31 (0.1–0.89)

Limitations

Not serious

Non-ACEi/ARB, 241

ACEi/ARB, 41

Non-ACEi/ARB, 63

ACEi/ARB, 4

Inconsistency

Serious

Indirectness

Not serious

Imprecision

Serious

Publication bias

Undetected

Quality

Moderate

Reynolds et al. (2020) [15]

New York University Langone Health (New York)

Retrospective cohort

1 Mar 2020 until 15 Apr 2020

N = 2005

Minimal grade 1

40 days

Heart failure, myocardial infarction, diabetes, chronic kidney disease, obstructive lung disease

N = 501

0.97 (0.79–1.19)

Limitations

Not serious

Non-ACEi/ARB, 986

ACEi/ARB, 1019

Non-ACEi/ARB, 249

ACEi/ARB, 252

Inconsistency

Serious

Indirectness

Not serious

Imprecision

Not serious

Publication bias

Undetected

Quality

High

Zhang et al (2020) [19]

Hubei’s Nine Hospital (China)

Retrospective cohort

31 Dec 2019 until 7 Mar 2020

N = 1128

Minimal grade 1

1 month

Diabetes, cardiac, or renal diseases

N = 99

0.34 (0.14–0.83)

Limitations

Not serious

Non-ACEi/ARB, 348

ACEi/ARB, 174

Non-ACEi/ARB, 92

ACEi/ARB, 7

Inconsistency

Serious

Indirectness

Not serious

Imprecision

Serious

Publication Bias

Undetected

Quality

Moderate